A Potential Biomarker for Treatment Response in Triple-negative Breast Cancer

New insights into tumor-induced B-cell changes in blood and bone marrow of triple-negative breast cancer (TNBC) patients show two distinct patterns of B-cell abnormalities that could serve as biomarkers for determining the likelihood of response to standard-of-care chemotherapy (SoC) and immunotherapy.

Authors

Peter Hofland (ORCID: https://orcid.org/0000-0002-8025-0434)

Publication Details

Journal: Onco Zine - The International Oncology Network
Published: 2024-09-13
DOI: https://doi.org/10.14229/onco.2024.09.13.021
Primary Topic: HER2/EGFR in Cancer Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A Potential Biomarker for Treatment Response in Triple-negative Breast Cancer

Peter Hofland

Sep 13, 2024

Onco Zine - The International Oncology Network

HER2/EGFR in Cancer Research

article

A Potential Biomarker for Treatment Response in Triple-negative Breast Cancer

Peter Hofland

September 13, 2024article en

Abstract

Onco Zine - The International Oncology Network

Openalex Percentile: Top 70%

HER2/EGFR in Cancer Research

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Potential Biomarker for Treatment Response in Triple-negative Breast Cancer — Peter Hofland · Onco Zine - The International Oncology Network (2024) | TGRS Research Map | TGRS